Athos Therapeutics Announces Proteomics Research Collaboration for Inflammatory Bowel Disease with Caltech
Athos will use specialized facilities and equipment at Caltech to perform molecular analysis and spectrometry-based proteomics on primary human single cells, blood, and tissue biopsies from de-identified Inflammatory Bowel Disease (IBD) patient samples. Thursday August 25, 11:00 am ET LOS ANGELES, August 25, 2022 — Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company […]
Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease
Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts. Monday July 11, 11:00 am ET LOS ANGELES, July 11, 2022 — Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases […]
Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from former President Obama, Appointed to the Board of Directors of Athos Therapeutics
LOS ANGELES, May 18, 2022 — Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Abraham Verghese, MD, MACP has been named to the Company’s Board of Directors. “I am honored to join the Athos Board of Directors,” […]
Athos Therapeutics Announces the Completion of its Oversubscribed Series A Financing
Athos Therapeutics Announces Research Collaboration with Cleveland Clinic to Advance Precision Medicine in Inflammatory Bowel Disease
Athos to perform a molecular analysis of patient samples from the Cleveland Clinic
Article: IBD Systems Biology is Here to Stay
The Athos SAB Chair, Dr. Claudio Fiocchi and the Athos CEO, Dr. Dimitrios Iliopoulos, have published an intriguing and informative article regarding the power of systems biology and how it relates to the treatment of IBD
Athos Therapeutics to Participate in both Biotech Showcase Digital and BIO @ JPM During “J.P. Morgan Week 2021”
Athos Therapeutics Announces Appointment of Chief Business Officer
LOS ANGELES, Nov. 2, 2020 /PRNewswire/ — Athos Therapeutics Inc., a late pre-clinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, today announced the appointment of Keith Bronson Hoffman, Ph.D. as their Chief Business Officer. In this role, Dr. Hoffman will oversee business development, funding, and partnerships, and will report […]
Athos Therapeutics is featured in Los Angeles Business Journal (June 15th issue)
Athos Therapeutics Inc. is featured in the cover of the June 15th issue of the Los Angeles Business Journal.
Opinion: Dr. Claudio Fiocchi “The need for AI-based precision therapy in inflammatory bowel disease”
The evolution of therapy for ulcerative colitis (UC) and Crohn’s disease (CD), the two main forms of inflammatory bowel disease (IBD), is a prolonged succession of vastly different approaches. After initial evidence of effectiveness of salazopyrine in UC patients in the 1940’s, many other medications were progressively introduced, including corticosteroids, aminosalycilates, immunosuppressors, antibiotics, and so […]